Compare IAC/Interactivecorp (PPLI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Sana Biotechnology Inc — how do they compare? IAC/Interactivecorp trades at $40.88 (market cap $3.05B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: IAC/Interactivecorp is far larger — about 3.6× Sana Biotechnology Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and Sana Biotechnology Inc for 23 Days on average.
| PPLI | SANA | |
|---|---|---|
Market Cap | $3.05B | $836.71M |
Volume | 931,019 | 4,507,444 |
Sector | Media | Health |
52-Week High | $47.62 | $5.92 |
52-Week Low | $31.52 | $2.68 |
Typical Hold Time | 79 Days | 23 Days |
Enterprise Value | $3.53B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.89, up 0.74% with strong analyst support (71% buy ratings) amid MGM acquisition speculation. The stock shows bullish technical momentum with recent earnings volatility - missing Q4 2025 and Q1 2026 but beating Q2 2026 expectations. Revenue declined to $2.39B in 2025 while maintaining healthy gross margins of 66.35%. The company's valuation appears attractive with P/E of 6.92 and P/B of 0.6, though negative cash flow of -$820M in 2025 raises concerns.
The outlook remains positive given potential MGM bid and improving 2026 profit projections (14.12% margin). Key risks include volatile earnings, declining revenue trends, and negative cash flow. With strong institutional support and takeover speculation, the stock offers upside potential but requires monitoring of operational turnaround and acquisition developments.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
